Axsome Therapeutics, Inc. (AXSM) Form 10-Q — Aug 10, 2026
Axsome Therapeutics reported Q2 2026 total revenues of $218.4 million, up 45.5% from $150.0 million a year earlier, with net product sales of $216.4 million across AUVELITY, SUNOSI, and SYMBRAVO. Net loss was $51.3 million, or $(0.99) per share, versus a $48.0 million loss in Q2 2025. Growth is being driven by commercial expansion: SYMBRAVO (FDA-approved January 2025) launched in June 2025, AUVELITY received an additional FDA approval in April 2026 with sales beginning June 2026, and in July 2026 the FDA accepted the AXS-12 NDA for cataplexy in narcolepsy with a PDUFA date of May 1, 2027.
Key figures
- Revenue
- 218375000
- Total Debt
- $190.0M principal outstanding at 6/30/26 ($120.0M Blackstone term loan + $70.0M revolver; revolver repaid in full in July 2026)
- Revenue Yoy
- +45.5% Q2 2026 vs Q2 2025; +50.9% H1 2026 vs H1 2025
- Total Assets
- 761447000
- Cash Position
- 319850000
- Interest Rate
- 9.58% effective on term loans (SOFR + 4.75%); revolver weighted-average 7.73% (SOFR + 4.00%)
- Maturity Date
- 2030 (principal due five years from May 8, 2025 closing)
- Shares Outstanding
- 52299889
- Rnd Q2 2026
- 46227000
- Sgna Q2 2026
- 208137000
- Axs12 Pdufa Date
- 2027-05-01
- Total Liabilities
- 678143000
- Accumulated Deficit
- 1421817000
- Advertising Q2 2026
- 55100000
- Stockholders Equity
- 83304000
- Product Sales H1 2026
- 405755000
- Product Sales Q2 2026
- 216355000
- Term Loan Outstanding
- 120000000
- Total Revenue H1 2026
- 409578000
- Atm Shares Sold Q2 2026
- 54644
- Antecip Royalty H1 2026
- 9900000
- Atm Gross Proceeds Q2 2026
- 13500000
- Axs20 Acquisition Upfront
- 10400000
- Customer Concentration Pct
- ["38","27","24"]
- Minimum Liquidity Covenant
- 30000000
- Takeda Milestone Potential
- 260000000
- Revolver Available At June30
- 20000000
- Contingent Consideration To Jazz
- 80334000
- Term Loan Available Until May2027
- 90000000
- Blackstone Facility Total Capacity
- 570000000
Price after filing
Close on the filing date to close N calendar days later (from $212.74). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.